Q-omics provides the consensus-scored LZTFL1 profile across patient tissues and cancer cell-line models. LZTFL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LZTFL1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, LZTFL1 protein abundance shows 23,146 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight BRCA, and THCA as cancer lineages where LZTFL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LZTFL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LZTFL1 survival associations across molecular data types. LZTFL1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LZTFL1 RNA expression–survival associations across cancer types. High LZTFL1 expression shows unfavorable associations in KICH and SCLC, but favorable associations in BRCA, UVM, KIRC and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LZTFL1 RNA expression.
This table summarizes LZTFL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LZTFL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LZTFL1 shows lower tumor expression in THCA, KIRC, LUSC, LUAD and KICH and higher tumor expression in COAD. The THCA box plot shows higher LZTFL1 RNA expression in normal versus tumor tissue (log2 FC = −0.824, t-test p < 0.001).
This table shows molecular features associated with LZTFL1 in patient tissues and cancer cell lines. In patient samples, LZTFL1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LZTFL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
